About
Respira Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing RT234, a novel inhalation therapy for pulmonary hypertension. The company aims to provide patients with an as-needed treatment option to manage their symptoms effectively. Respira focuses on innovative delivery methods that enhance drug efficacy for pulmonary disease.
Albuquerque